度普利尤单抗治疗特应性皮炎的研究进展  

Recent Advances in Dupilumab for Atopic Dermatitis Treatment

作　　者：孙莉婷 张江安[1,2,3,4,5,6,7,8,9,10,11] 于建斌 SUN Li-ting;ZHANG Jiang'an;YU Jian-bin(Department of Dermatology,First Afiliated Hospital,Zhengzhou University,Ahengzhou 450000,China)

机构地区：[1]郑州大学第一附属医院皮肤科,河南郑州450000 [2]中国医师协会皮肤科医师分会罕见病遗传病专业委员会 [3]河南省变态反应分会 [4]河南省医学会皮肤病分会 [5]河南省性与性病学会 [6]河南省医师协会皮肤科医师分会 [7]河南省医学会皮肤病分会银屑病学组 [8]河南省中医药学会皮肤科分会 [9]河南省抗癌协会皮肤肿瘤专委会 [10]中国皮肤性病学杂志 [11]中华皮肤科杂志

出　　处：《皮肤科学通报》2020年第5期525-533,M0007,共10页Dermatology Bulletin

摘　　要：特应性皮炎(Atopic dermatitis,AD)是一种常见的慢性、复发性、炎症性、系统性疾病,以剧烈瘙痒和多形性皮疹为主要临床表现,患者常合并过敏性鼻炎、哮喘等其他特应性疾病。对于中、重度的难治性AD,缺乏一种低风险且有效的系统性药物。度普利尤单抗(Dupilum-ab)是由Regeneron和Sanofi联合开发的一种全人源化IgG4亚类单克隆抗体,是全球首个也是迄今唯一治疗成人中重度特应性皮炎的靶向生物制剂。度普利尤单抗通过与IL4Ro亚单位结合来抑制IL-4和IL-13信号及下游的信号转导。本文对度普利尤单抗治疗中重度AD患者的研究进展进行综述。Atopice dermatitis(AD)is a common chronic,recurrent,inflammatory,and systemic disease characterized by recurrent sever pruritus and eczematous lesions.Patients often have other atopic diseases such as allergic rhinitis and asthma.There is lack of an effective drug with low risk profile for patients with moderate-to-severe,refractory atopic dermatitis.Dupilumab is a fully human lIgG4 monoclonal antibody developed by Regeneron and Sanofi.It is the world's first and so far the only targeted biologic therapy approved for the treatment of moderate-to-severe atopic dermatitis in adults.Dupilumab binds to IL4Ra subunit to inhibit IL.4 and IL-I13 signaling and the downstrem signal transduction.The update of dupilumab for treating moderate-to-severe AD is reviewed in this article.

关 键 词：度普利尤单抗 中重度特应性皮炎 TH2 IL4 IL-13 

分 类 号：R917[医药卫生—药物分析学]